![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MMP24 |
Gene summary for MMP24 |
![]() |
Gene information | Species | Human | Gene symbol | MMP24 | Gene ID | 10893 |
Gene name | matrix metallopeptidase 24 | |
Gene Alias | MMP-24 | |
Cytomap | 20q11.22 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q86VV6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10893 | MMP24 | RNA-P17T-P17T-2 | Human | Lung | IAC | 5.30e-08 | 7.55e-01 | 0.3371 |
10893 | MMP24 | RNA-P17T-P17T-4 | Human | Lung | IAC | 1.48e-03 | 5.42e-01 | 0.343 |
10893 | MMP24 | RNA-P17T-P17T-6 | Human | Lung | IAC | 1.13e-06 | 6.21e-01 | 0.3385 |
10893 | MMP24 | RNA-P17T-P17T-8 | Human | Lung | IAC | 5.26e-09 | 7.38e-01 | 0.3329 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Lung | ![]() | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ | ||
IAC: Invasive lung adenocarcinoma | ||
MIA: Minimally invasive adenocarcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00987274 | Lung | IAC | maintenance of cell number | 25/2061 | 134/18723 | 5.73e-03 | 4.18e-02 | 25 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0492810 | Lung | IAC | Parathyroid hormone synthesis, secretion and action | 26/1053 | 106/8465 | 4.34e-04 | 4.03e-03 | 2.68e-03 | 26 |
hsa0492811 | Lung | IAC | Parathyroid hormone synthesis, secretion and action | 26/1053 | 106/8465 | 4.34e-04 | 4.03e-03 | 2.68e-03 | 26 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MMP24 | SNV | Missense_Mutation | c.706G>C | p.Asp236His | p.D236H | Q9Y5R2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MMP24 | SNV | Missense_Mutation | c.785N>C | p.Glu262Ala | p.E262A | Q9Y5R2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0AT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MMP24 | SNV | Missense_Mutation | novel | c.503N>A | p.Ile168Asn | p.I168N | Q9Y5R2 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MMP24 | SNV | Missense_Mutation | c.1690N>T | p.Arg564Cys | p.R564C | Q9Y5R2 | protein_coding | deleterious(0) | probably_damaging(0.925) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MMP24 | SNV | Missense_Mutation | rs777650805 | c.1283N>A | p.Arg428His | p.R428H | Q9Y5R2 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-PL-A8LV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MMP24 | insertion | In_Frame_Ins | novel | c.631_632insACTGGGACCTGAATCATAATAGTG | p.Ile211delinsAsnTrpAspLeuAsnHisAsnSerVal | p.I211delinsNWDLNHNSV | Q9Y5R2 | protein_coding | TCGA-A8-A083-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MMP24 | insertion | In_Frame_Ins | novel | c.1719_1720insCCTGGCCAGATGCAGAATGGGCCTCCAGGA | p.Glu573_Val574insProGlyGlnMetGlnAsnGlyProProGly | p.E573_V574insPGQMQNGPPG | Q9Y5R2 | protein_coding | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MMP24 | insertion | Nonsense_Mutation | novel | c.1049_1050insTGAAAGTACTCTCTA | p.Pro350_Ser351insGluSerThrLeuTer | p.P350_S351insESTL* | Q9Y5R2 | protein_coding | TCGA-BH-A0GY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyotxan | SD | ||
MMP24 | SNV | Missense_Mutation | rs746624950 | c.1069N>T | p.Arg357Cys | p.R357C | Q9Y5R2 | protein_coding | deleterious(0.03) | probably_damaging(0.962) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MMP24 | SNV | Missense_Mutation | novel | c.1767C>G | p.Ile589Met | p.I589M | Q9Y5R2 | protein_coding | deleterious(0.05) | probably_damaging(0.985) | TCGA-VS-AA62-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |